Vantive Health

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Vantive Health sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials 1 currently recruiting 10 completed later-stage tilt top decile by trial count

Vantive Health: 15 sponsored US clinical trials, 1 recruiting.

Vantive Health sponsors 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Kidney Injury (AKI), with 2 trials.

Top-decile sponsor footprint

Vantive Health ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 18/100

10 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

15 total, page 1 of 1

RECRUITING Phase 3

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

NCT05399537

COMPLETED

Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry

NCT06633029

TERMINATED NA

Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)

NCT03812679

COMPLETED NA

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

NCT03257410

TERMINATED Phase 3

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

NCT02860130

TERMINATED NA

Prismaflex HF20 Set and Prismaflex® System 7.10/7.20 for Acute Continuous Renal Replacement Therapy (CRRT) in Children

NCT02561247

COMPLETED NA

A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis

NCT01181544

COMPLETED NA

Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate

NCT00962000

COMPLETED

Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer

NCT00659724

COMPLETED NA

Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers

NCT00636389

COMPLETED NA

Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis

NCT00636077

COMPLETED

Ease of Use Study for the Gambro Polyflux HD-C4 Small Dialyzer

NCT00579202

TERMINATED Phase 2

Heart Failure and Peritoneal Ultrafiltration

NCT00368641

COMPLETED NA

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

NCT00287235

COMPLETED NA

Gambro AK200 ULTRA Hemodiafiltration Study

NCT01202708

Where Vantive Health enrollment is open (later-stage tilt)

1 recruiting of 15 indexed (7% open); 10 completed (67%).

Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Acute Kidney Injury (AKI) (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Vantive Health: open-pipeline peers nationwide

Peers matched on 15 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Vantive Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 14.914.91515.1 0%10%20%30%40% Total trials Recruiting share Vantive HealthAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead PharmaceuticalsBaylor Breast Care CenterGeron CorporationGuerbetJoanne Kurtzberg, MD
Vantive Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vantive Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

What to do with this Vantive Health page

15 registered trials is a research-attention snapshot, not an endorsement of Vantive Health or any single study.

  • 1 of Vantive Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Kidney Injury (AKI) is the condition Vantive Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Kidney Injury (AKI) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vantive Health pipeline card: 15 registered trials from official public datasets.Report a data error.